NEUFELD, Austria, Feb. 25, 2025 /PRNewswire/ -- Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The Netherlands). The multicentric prospective...
Hence then, the article about sanochemia spl investigational iron based mri contrast agent meets primary endpoints in pivotal phase iii study was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study )
Also on site :
- Greg Evigan Shares Sweet ‘My Two Dads’ Throwback With Paul Reiser and Staci Keanan: ‘I Adore These 2 People!’
- JoAnna Garcia Swisher Breaks Her Silence After Shocking ‘Sweet Magnolias’ Cancellation: ‘How Do You Say Goodbye?’
- Carole King Wrote ‘Will You Love Me Tomorrow’ at 18 and It Became the First No. 1 Song by Any Girl Group; She Sang It 11 Years Later on Tapestry